Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02712723
Title	Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (FELINE)
Acronym	FELINE
Recruitment	Unknown status
Gender	female
Phase	Phase II
Variant Requirements	No
Sponsors	Qamar Khan
Indications	Her2-receptor negative breast cancer
Therapies	Letrozole + Ribociclib
Age Groups:	adult
Covered Countries	USA

Facility	City	State	Zip	Country	Details
University of Arkansas for Medical Sciences	Little Rock	Arkansas	72205	United States	Details
City of Hope National Medical Center	Duarte	California	91010	United States	Details
Cancer Research Collaboration	Santa Ana	California	92705	United States	Details
University of Miami Sylvester Comprehensive Cancer Center	Deerfield Beach	Florida	33442	United States	Details
University of Kansas Cancer Center - West	Kansas City	Kansas	66112	United States	Details
University of Kansas Cancer Center - Overland Park	Overland Park	Kansas	66210	United States	Details
University of Kansas Cancer Center - Westwood	Westwood	Kansas	66205	United States	Details
Massachusetts General Hospital	Boston	Massachusetts	02114	United States	Details
University of Kansas Cancer Center - South	Kansas City	Missouri	64131	United States	Details
University of Kansas Cancer Center - North	Kansas City	Missouri	64154	United States	Details
University of Kansas Cancer Center - Lee's Summit	Lee's Summit	Missouri	64064	United States	Details
Columbia University Medical Center	New York	New York	10032	United States	Details
University of Wisconsin Carbone Cancer Center	Madison	Wisconsin	53705	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field